MX341324B - Polipeptidos. - Google Patents
Polipeptidos.Info
- Publication number
- MX341324B MX341324B MX2013013913A MX2013013913A MX341324B MX 341324 B MX341324 B MX 341324B MX 2013013913 A MX2013013913 A MX 2013013913A MX 2013013913 A MX2013013913 A MX 2013013913A MX 341324 B MX341324 B MX 341324B
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptides
- pramlintide
- medicaments
- analogue
- amino acid
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- NRKVKVQDUCJPIZ-MKAGXXMWSA-N pramlintide acetate Chemical class C([C@@H](C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CS)NC(=O)[C@@H](N)CCCCN)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 NRKVKVQDUCJPIZ-MKAGXXMWSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57527—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/225—Calcitonin gene related peptide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
Abstract
La presente invención se refiere a polipéptidos que comprenden una secuencia de aminoácidos que es un análogo de pramlintide, composiciones farmacéuticas que comprenden estos polipéptidos, y estos polipéptidos para usarse como medicamentos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11169405 | 2011-06-10 | ||
| US201161496113P | 2011-06-13 | 2011-06-13 | |
| PCT/EP2012/060900 WO2012168432A1 (en) | 2011-06-10 | 2012-06-08 | Polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013013913A MX2013013913A (es) | 2013-12-16 |
| MX341324B true MX341324B (es) | 2016-08-16 |
Family
ID=47295518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013013913A MX341324B (es) | 2011-06-10 | 2012-06-08 | Polipeptidos. |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US8575090B2 (es) |
| EP (3) | EP2718314A2 (es) |
| JP (3) | JP6121992B2 (es) |
| KR (1) | KR102066987B1 (es) |
| CN (3) | CN103649115B (es) |
| AU (1) | AU2012266269B2 (es) |
| BR (1) | BR112013031268B1 (es) |
| CA (1) | CA2838884C (es) |
| ES (1) | ES2664509T3 (es) |
| IL (1) | IL229258B (es) |
| MX (1) | MX341324B (es) |
| MY (1) | MY161773A (es) |
| PL (1) | PL2718316T3 (es) |
| RS (1) | RS59977B1 (es) |
| RU (1) | RU2669999C2 (es) |
| SI (1) | SI2718316T1 (es) |
| WO (3) | WO2012168430A2 (es) |
| ZA (1) | ZA201309174B (es) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012168430A2 (en) | 2011-06-10 | 2012-12-13 | Novo Nordisk A/S | Polypeptides |
| US8575091B1 (en) * | 2012-04-19 | 2013-11-05 | Novo Nordisk A/S | Amylin analogues and pharmaceutical compositions thereof |
| LT3004155T (lt) | 2013-05-28 | 2021-12-27 | Takeda Pharmaceutical Company Limited | Peptidų junginys |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| JP6728141B2 (ja) * | 2014-09-04 | 2020-07-22 | ノヴォ ノルディスク アー／エス | 新規のアミリン及びカルシトニン受容体アゴニスト |
| JP2018012644A (ja) * | 2014-11-26 | 2018-01-25 | 武田薬品工業株式会社 | ペプチド化合物 |
| US20170368375A1 (en) | 2014-12-23 | 2017-12-28 | Colgate-Palmolive Company | Oral Care Composition |
| CN105985995A (zh) * | 2015-01-29 | 2016-10-05 | 暨南大学 | 一种利用家蚕生物反应器生产普兰林肽(pa)的方法 |
| CN107567459B (zh) * | 2015-03-18 | 2021-09-24 | 西兰制药公司 | 胰淀素类似物 |
| CN106554405B (zh) * | 2015-09-30 | 2020-04-24 | 深圳翰宇药业股份有限公司 | 一种多肽及其用途、制备方法 |
| CN106928086B (zh) * | 2015-12-31 | 2019-05-31 | 深圳翰宇药业股份有限公司 | 一种长链化合物的制备方法 |
| CN109477094B (zh) | 2016-05-24 | 2022-04-26 | 武田药品工业株式会社 | 肽化合物 |
| TWI784968B (zh) | 2016-09-09 | 2022-12-01 | 丹麥商西蘭製藥公司 | 澱粉素類似物 |
| MA46780A (fr) | 2016-11-07 | 2019-09-11 | Novo Nordisk As | Esters à dchbs actif de composés peg et leur utilisation |
| TWI847306B (zh) | 2017-08-24 | 2024-07-01 | 丹麥商諾佛 儂迪克股份有限公司 | Ｇｌｐ-１組成物及其用途 |
| IL282079B2 (en) | 2018-10-11 | 2025-09-01 | Intarcia Therapeutics Inc | Human amylin analog polypeptides and methods of use |
| AU2020223031B2 (en) | 2019-02-12 | 2024-08-29 | Ambrx, Inc. | Compositions containing, methods and uses of antibody-TLR agonist conjugates |
| JP7505713B2 (ja) | 2019-02-22 | 2024-06-25 | ロヨラ メリーマウント ユニバーシティ | アミロイドペプチドバリアント |
| EP3930757A1 (en) | 2019-03-01 | 2022-01-05 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
| PE20221168A1 (es) | 2019-11-11 | 2022-07-25 | Boehringer Ingelheim Int | Agonistas del receptor npy2 |
| BR112022013795A2 (pt) * | 2020-02-18 | 2022-09-13 | Novo Nordisk As | Composição farmacêutica líquida, e, kit |
| UA130066C2 (uk) | 2020-08-07 | 2025-10-29 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | Розчинні агоністи рецепторів npy2 |
| AU2021327396A1 (en) | 2020-08-20 | 2023-03-23 | Ambrx, Inc. | Antibody-TLR agonist conjugates, methods and uses thereof |
| SI4021929T1 (sl) | 2020-09-24 | 2023-09-29 | Gubra Aps | Analogi HAM15-52 z izboljšano močjo receptorja za amilin(HAMY3R) |
| TW202440619A (zh) | 2020-12-18 | 2024-10-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1及澱粉素受體之共促效劑 |
| TW202400632A (zh) * | 2021-03-03 | 2024-01-01 | 美商美國禮來大藥廠 | 長效澱粉素受體促效劑及其用途 |
| EP4313163A1 (en) | 2021-04-03 | 2024-02-07 | Ambrx, Inc. | Anti-her2 antibody-drug conjugates and uses thereof |
| WO2022248419A2 (en) | 2021-05-22 | 2022-12-01 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4144362A1 (en) | 2021-09-06 | 2023-03-08 | Adocia | Compositions comprising short-acting hormones for treating or preventing obesity and pumps comprising said composition |
| EP4129324A1 (en) | 2021-08-02 | 2023-02-08 | Adocia | Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist |
| WO2023086499A1 (en) | 2021-11-10 | 2023-05-19 | I2O Therapeutics, Inc. | Ionic liquid compositions |
| WO2023110833A1 (en) | 2021-12-13 | 2023-06-22 | Novo Nordisk A/S | Pharmaceutical formulations comprising a cyclodextrin |
| WO2023187067A1 (en) | 2022-03-30 | 2023-10-05 | Novo Nordisk A/S | Formulation method |
| WO2023227133A1 (zh) * | 2022-05-27 | 2023-11-30 | 杭州先为达生物科技股份有限公司 | 人胰淀素类似物、其衍生物及用途 |
| IL319599A (en) | 2022-09-19 | 2025-05-01 | Zealand Pharma As | Combination therapy |
| US12116388B2 (en) | 2022-12-22 | 2024-10-15 | Novo Nordisk A/S | Amylin receptor agonists |
| KR20250127104A (ko) | 2022-12-22 | 2025-08-26 | 노보 노르디스크 에이/에스 | 아밀린 수용체 작용제 |
| AU2024218747A1 (en) * | 2023-02-10 | 2025-08-28 | Hangzhou Sciwind Biosciences Co., Ltd. | Polypeptide and derivative thereof, composition, and use thereof |
| AR132977A1 (es) | 2023-06-15 | 2025-08-13 | Novo Nordisk As | Formulaciones farmacéuticas que comprenden una ciclodextrina |
| TW202515598A (zh) | 2023-06-21 | 2025-04-16 | 丹麥商西蘭製藥公司 | 具有增進性能之類似物 |
| WO2024261076A1 (en) | 2023-06-21 | 2024-12-26 | Zealand Pharma A/S | Weight loss |
| TW202517291A (zh) | 2023-06-30 | 2025-05-01 | 丹麥商西蘭製藥公司 | 組合療法 |
| TW202540155A (zh) | 2023-11-30 | 2025-10-16 | 丹麥商諾佛 儂迪克股份有限公司 | Glp-1、gip及澱粉素受體之三重促效劑 |
| WO2025160082A1 (en) * | 2024-01-23 | 2025-07-31 | Viking Therapeutics, Inc. | Amylin analogs |
| TW202545982A (zh) * | 2024-02-07 | 2025-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 胰島澱粉樣多肽類似物及其醫藥用途 |
| EP4684802A1 (en) | 2024-07-23 | 2026-01-28 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| WO2025172605A1 (en) | 2024-02-16 | 2025-08-21 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4603080A1 (en) | 2024-02-16 | 2025-08-20 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4684801A1 (en) | 2024-07-23 | 2026-01-28 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| WO2025172606A1 (en) | 2024-02-16 | 2025-08-21 | Adocia | Composition comprising semaglutide, cagrilintide and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
| EP4603079A1 (en) | 2024-02-16 | 2025-08-20 | Adocia | Composition comprising a peptide having an isoelectric point of less than 6.5 and a co-polyamino acid bearing carboxylate charges and hydrophobic radicals |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA936811B (en) * | 1992-10-28 | 1995-03-15 | Upjohn Co | Somatotropin modifications |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| ES2356595T3 (es) | 1998-02-13 | 2011-04-11 | Amylin Pharmaceuticals, Inc. | Nuevos compuestos de actividad mixta de la amilina. |
| AU3538799A (en) * | 1998-04-30 | 1999-11-23 | Kirin Brewery Company, Limited | Human thrombopoietin mutants |
| US6890531B1 (en) * | 1998-07-31 | 2005-05-10 | Kirin Beer Kabushiki Kaisha | Neuronal growth factor galectin-1 |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| JP2008500816A (ja) * | 2004-03-31 | 2008-01-17 | ゼンコー・インコーポレイテッド | 改善された性質を有するｂｍｐ−７変異体 |
| WO2007104789A2 (en) * | 2006-03-15 | 2007-09-20 | Novo Nordisk A/S | Amylin derivatives |
| WO2008086086A2 (en) * | 2007-01-05 | 2008-07-17 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility in physiological ph buffers |
| EP2036923A1 (en) * | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| JP2011525895A (ja) | 2008-06-25 | 2011-09-29 | ノボ・ノルデイスク・エー／エス | アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド |
| WO2010046357A1 (en) * | 2008-10-21 | 2010-04-29 | Novo Nordisk A/S | Amylin derivatives |
| CN102639559B (zh) * | 2009-11-25 | 2015-04-29 | 诺沃—诺迪斯克有限公司 | 用于制备多肽的方法 |
| WO2012168430A2 (en) | 2011-06-10 | 2012-12-13 | Novo Nordisk A/S | Polypeptides |
-
2012
- 2012-06-08 WO PCT/EP2012/060897 patent/WO2012168430A2/en not_active Ceased
- 2012-06-08 EP EP12729416.3A patent/EP2718314A2/en not_active Withdrawn
- 2012-06-08 US US13/491,880 patent/US8575090B2/en active Active
- 2012-06-08 EP EP12729418.9A patent/EP2718316B1/en active Active
- 2012-06-08 CN CN201280028642.1A patent/CN103649115B/zh active Active
- 2012-06-08 CN CN201280028644.0A patent/CN103596973A/zh active Pending
- 2012-06-08 SI SI201231728T patent/SI2718316T1/sl unknown
- 2012-06-08 US US13/491,883 patent/US8741836B2/en active Active
- 2012-06-08 EP EP12729417.1A patent/EP2718315B1/en active Active
- 2012-06-08 MX MX2013013913A patent/MX341324B/es active IP Right Grant
- 2012-06-08 CA CA2838884A patent/CA2838884C/en active Active
- 2012-06-08 BR BR112013031268-8A patent/BR112013031268B1/pt active IP Right Grant
- 2012-06-08 JP JP2014514091A patent/JP6121992B2/ja active Active
- 2012-06-08 ES ES12729417.1T patent/ES2664509T3/es active Active
- 2012-06-08 MY MYPI2013004133A patent/MY161773A/en unknown
- 2012-06-08 WO PCT/EP2012/060900 patent/WO2012168432A1/en not_active Ceased
- 2012-06-08 RS RS20200191A patent/RS59977B1/sr unknown
- 2012-06-08 JP JP2014514092A patent/JP6247205B2/ja active Active
- 2012-06-08 US US13/491,885 patent/US8722849B2/en active Active
- 2012-06-08 RU RU2013156937A patent/RU2669999C2/ru active
- 2012-06-08 CN CN201280028554.1A patent/CN103596972B/zh active Active
- 2012-06-08 AU AU2012266269A patent/AU2012266269B2/en active Active
- 2012-06-08 KR KR1020137034732A patent/KR102066987B1/ko active Active
- 2012-06-08 JP JP2014514090A patent/JP2014519509A/ja active Pending
- 2012-06-08 PL PL12729418T patent/PL2718316T3/pl unknown
- 2012-06-08 WO PCT/EP2012/060899 patent/WO2012168431A2/en not_active Ceased
-
2013
- 2013-09-26 US US14/038,265 patent/US9029325B2/en active Active
- 2013-11-05 IL IL22925813A patent/IL229258B/en active IP Right Grant
- 2013-12-05 ZA ZA2013/09174A patent/ZA201309174B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013013913A (es) | Polipeptidos. | |
| MX2012007806A (es) | Composiciones farmaceuticas para administracion oral de peptidos de insulina. | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| EP4414376A3 (en) | Novel depsipeptide and uses thereof | |
| MD20150091A2 (ro) | Compuşi antivirali | |
| HK1206636A1 (zh) | 用於制备肿瘤相关蛋白和多肽的修饰的多核苷酸 | |
| MX348823B (es) | Formulaciones estables de linaclotida. | |
| PH12014501514A1 (en) | New azetidine derivatives, pharmaceutical compositions and uses thereof | |
| MX349004B (es) | Nuevos compuestos. | |
| MX2013000958A (es) | Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma. | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| UA109661C2 (uk) | Фармацевтична композиція співкристалів трамадолу і коксибів | |
| PH12015500713A1 (en) | Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases | |
| GEP201706621B (en) | Benzamides | |
| MX2014010433A (es) | Nueva forma cristalina de sulfato de sitagliptina. | |
| MX362879B (es) | Usos novedosos. | |
| PH12017500089A1 (en) | Aldosterone synthase inhibitors | |
| PH12016501686A1 (en) | Pharmaceutical compositions of sitagliptin | |
| UA113540C2 (xx) | Поліморфи n-(2-метоксибензоїл)-4-$(метиламінокарбоніл)аміно]бензолсульфонаміду | |
| IN2014DN03010A (es) | ||
| SG10201808383UA (en) | Cyclic apelin analogs | |
| MX2014004742A (es) | Nuevos agentes antibacterianos de fenicol. | |
| TR201106224A2 (tr) | Solunum yolu hastalıkları tedavisinde kullanılan farmasötik bileşimler. | |
| IN2013MU02279A (es) | ||
| UA110793C2 (uk) | Піразолілхіноксалінові інгібітори кінази |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |